Skip Navigation

European Heart Journal 2002 23(22):1738-1752; doi:10.1053/euhj.2002.3329
Copyright © 2002 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (28)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Stangl, V.
Right arrow Articles by Stangl, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stangl, V.
Right arrow Articles by Stangl, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Reviews

Coronary atherogenic risk factors in women

V. Stanglf1, G. Baumann and K. Stangl

Medizinische Klinik mit Schwerpunkt Kardiologie, Angiologie, Pneumologie, Charité, Campus Mitte, Humboldt-Universität Berlin, Germany

revised June 11, 2002; accepted June 12, 2002

Key Words: Atherosclerosis, coronary heart disease, risk factor, female, gender.

f1 Correspondence: Verena Stangl, MD, Med. Klinik mit Schwerpunkt Kardiologie, Angiologie, Pneumologie, Schumannstr. 20/21, D-10117 Berlin, Germany.

References

  1. Federal Statistical Office, Germany, yearbook 2000, 18, 424, 5
  2. Garber AM, Browner WS, Hulley SB. Cholesterol screening in asymptomatic adults, revisited. Ann Intern Med. 1996;124:518–531[Abstract/Free Full Text]
  3. Simons LA. Interrelation of lipids and lipoproteins with coronary artery disease mortality in 19 countries. Am J Cardiol. 1986;57:5G–10G[CrossRef][Medline]
  4. Kuulasmaa K, Tunstall-Pedoe H, Dobson A. Estimation of contribution of changes in classic risk factors to trends in coronary event-rates across the WHO MONICA Project populations. Lancet. 2000;355:675–687[CrossRef][ISI][Medline]
  5. Anderson KM, Castelli WP, Levy D. Cholesterol and mortality: 30 years of follow-up from the Framingham study. JAMA. 1987;257:2176–2180[Abstract]
  6. Keil U. Coronary artery disease: the role of lipids, hypertension and smoking. Basic Res Cardiol. 2000;95:I/52–I/58
  7. Castelli WP. Cholesterol and lipids in the risk of coronary artery disease: the Framingham Heart Study. Can J Cardiol. 1988;4:5A–10A
  8. Keil U, Liese AD, Hense HW. Classical risk factors and their impact on incident non-fatal and fatal myocardial infarction and all cause mortality in southern Germany. Results from the MONICA Augsburg cohort study 1984–1992. Monitoring Trends and Determinants in Cardiovascular Diseases. Eur Heart J. 1998;19:1197–1207[Abstract/Free Full Text]
  9. Maron DJ. The epidemiology of low levels of high-density lipoprotein cholesterol in patients with and without coronary artery disease. Am J Cardiol. 2000;86:11L–14L[CrossRef][ISI][Medline]
  10. Johnson CL, Rifkind BM, Sempos CT. Declining serum total cholesterol levels among US adults: the National Health and Nutrition Examination Surveys. JAMA. 1993;269:3002–3008[Abstract]
  11. Matthews KA, Meilahn E, Kuller LH, Kelsey SF, Caggiula AW, Wing RR. Menopause and risk factors for coronary heart disease. N Engl J Med. 1989;321:641–646[Abstract]
  12. Stevenson JC, Crook D, Godsland IF. Influence of age and menopause on serum lipids and lipoproteins in healthy women. Atherosclerosis. 1993;98:83–90[CrossRef][ISI][Medline]
  13. Gordon DJ, Probstfield JL, Garrison RJ. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation. 1989;79:8–15[Abstract/Free Full Text]
  14. Kannel WB, Wilson PW. Risk factors that attenuate the female coronary disease advantage. Arch Intern Med. 1995;155:57–61[Abstract]
  15. Welty FK. Cardiovascular disease and dsylipidemia in women. Arch Intern Med. 2001;161:514–522[Abstract/Free Full Text]
  16. Corti MC, Guralnik JM, Salive ME. HDL cholesterol predicts coronary heart disease mortality in older persons. JAMA. 1995;274:539–544[Abstract]
  17. Rich-Edwards JW, Manson JE, Hennekens CH, Buring JE. The primary prevention of coronary heart disease in women. N Engl J Med. 1995;332:1758–1766[Free Full Text]
  18. Kannel WB. Contributions of the Framingham Study to the conquest of coronary artery disease. Am J Cardiol. 1988;62:1109–1112[CrossRef][ISI][Medline]
  19. Manolio TA, Pearson TA, Wenger NK, Barrett-Connor E, Payne GH, Harlan WR. Cholesterol and heart disease in older persons and women: review of an NHLBI workshop. Ann Epidemiol. 1992;2:161–176[Medline]
  20. Superko HR. Did grandma give you heart disease? The new battle against coronary artery disease. Am J Cardiol. 1998;82:34–46[CrossRef]
  21. Superko HR. Lipoprotein subclasses and atherosclerosis. Front Bioscience. 2001;6:355–365
  22. Reaven GM, Chen YDI, Jeppesen J, Maheux P, Krauss RM. Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles. J Clin Invest. 1993;92:141–146[ISI][Medline]
  23. Kwiterovich PO Jr. The metabolic pathways of high-density lipoprotein, low-density lipoprotein, and triglycerides: a current review. Am J Cardiol. 2000;86:5L–10L[ISI][Medline]
  24. Packard C, Caslake M, Shepherd J. The role of small, dense low density lipoprotein (LDL): a new look. Int J Cardiol. 2000;74:S17–S22[CrossRef]
  25. Krauss RM, Blanche PJ. Detection and quantification of LDL subfractions. Curr Opin Lipidol. 1992;3:377–383[CrossRef]
  26. Carr MC, Kim KH, Zambon A. Changes in LDL density across the menopausal transition. J Investig Med. 2000;48:245–250[ISI][Medline]
  27. Anber V, Griffin BA, McConnell M. Influence of plasma lipid and LDL-subfraction profile on the interaction between low density lipoprotein with human arterial wall proteoglycans. Atherosclerosis. 1996;124:261–271[CrossRef][ISI][Medline]
  28. Tornvall P, Karpe F, Carlson LA, Hamsten A. Relationship of low density lipoprotein subfractions to angiographically defined coronary artery disease in young survivors of myocardial infarction. Atherosclerosis. 1991;90:67–80[CrossRef][ISI][Medline]
  29. Campos H, Genest JJ Jr, Blijlevens E. Low density lipoprotein particle size and coronary artery disease. Arterioscler Thromb. 1992;12:187–195[Abstract/Free Full Text]
  30. Campos H, Moye LA, Glasser SP, Stampfer MJ, Sacks FM. Low-density lipoprotein size, pravastatin treatment, and coronary events. JAMA. 2001;286:1468–1474[Abstract/Free Full Text]
  31. Ruotolo G, Tettamanti C, Garancini MP. Smaller, denser LDL particles are not a risk factor for cardiovascular disease in healthy nonagenarian women of Cremona Population Study. Atherosclerosis. 1998;140:65–70[CrossRef][ISI][Medline]
  32. Gardner CD, Fortmann SP, Krauss RM. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA. 1996;276:875–881[Abstract]
  33. Stampfer MJ, Krauss RM, Ma J. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA. 1996;276:882–888[Abstract]
  34. Gotto AM Jr. Triglyceride as a risk factor for coronary artery disease. Am J Cardiol. 1998;82:22Q–25Q[ISI][Medline]
  35. Gotto AM Jr. Triglyceride. A forgotten risk factor. Circulation. 1998;97:1027–1028[Free Full Text]
  36. Rubins HB, Robins S, Collins D. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med. 1999;341:410–418[Abstract/Free Full Text]
  37. Miller M. Differentiating the effects of raising low levels of high-density lipoprotein cholesterol versus lowering normal triglycerides: further insights from the Veterans Affairs High-Density Lipoprotein Intervention Trial. Am J Cardiol. 2000;86:23L–27L[ISI][Medline]
  38. Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Am J Cardiol. 1992;70:733–737[CrossRef][ISI][Medline]
  39. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. Circulation. 1998;97:1029–1036[Abstract/Free Full Text]
  40. Miller M, Seidler A, Moalemi A, Pearson TA. Normal triglyceride levels and coronary artery disease events: the Baltimore Coronary Observational Long-Term Study. J Am Coll Cardiol. 1998;31:1252–1257[Abstract/Free Full Text]
  41. Castelli WP. Epidemiology of triglycerides: a view from Framingham. Am J Cardiol. 1992;70:3H–9H[CrossRef][Medline]
  42. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk. 1996;3:213–219[Medline]
  43. Lapidus L, Bengtsson C, Lindquist O, Sigurdsson JA, Ryboe E. Triglycerides—main lipid risk factor for cardiovascular disease in women? Acta Med Scand. 1985;217:481–489[ISI][Medline]
  44. D'Agostino RB, Russell MW, Huse DM. Primary and subsequent coronary risk appraisal: New results from the Framingham Study. Am Heart J. 2000;139:272–281[ISI][Medline]
  45. Plow EF, Miles LA. Relationship between plasminogen receptors and Lp(a). Scanu AM. Lipoprotein (a). San Diego: Academic Press; 1990.
  46. Etingin OR, Hajjar DP, Hajjar KA, Harperl PC, Nachman RL. Lipoprotein (a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. A potential mechanism in thrombogenesis. J Biol Chem. 1991;266:2459–2465[Abstract/Free Full Text]
  47. Scanu AM, Lawn RM, Berg K. Lipoprotein (a) and atherosclerosis. Ann Intern Med. 1991;115:209–218[ISI][Medline]
  48. Craig WY, Neveux LM, Palomaki GE, Cleveland MM, Haddow JE. Lipoprotein (a) as a risk factor for ischemic heart disease: metaanalysis of prospective studies. Clin Chem. 1998;44:2301–2306[Abstract/Free Full Text]
  49. Budde T, Fechtrup C, Bösenberg E. Plasma Lp(a) levels correlate with number, severity, and length extension of coronary lesions in male patients undergoing coronary arteriography for clinically suspected coronary atherosclerosis. Arterioscler Thromb. 1994;14:1730–1736[Abstract/Free Full Text]
  50. Terres W, Tatsis E, Pfalzer B, Beil U, Beisiegel U, Hamm CW. Rapid angiographic progression of coronary artery disease in patients with elevated lipoprotein (a). Circulation. 1995;91:948–950[Abstract/Free Full Text]
  51. Enas EA. Lipoprotein (a) as a determinant of coronary heart disease in young women: a stronger risk factor than diabetes? Circulation. 1998;97:293–295[Free Full Text]
  52. Solymoss BC, Marcil M, Wesolowska E, Gilfix BM, Lespérance, Campeau L. Relation of coronary artery disease in women <60 years of age to the combined elevation of serum lipoprotein (a) and total cholesterol to high-density cholesterol ratio. Am J Cardiol. 1993;72:1215–1219[CrossRef][ISI][Medline]
  53. Orth-Gomer K, Mittleman MA, Schenck-Gustafsson K. Lipoprotein (a) as a determinant of coronary heart disease in young women. Circulation. 1997;95:329–334[Abstract/Free Full Text]
  54. Hahmann HW, Schätzer-Klotz D, Bunte T, Becker D, Schieffer HJ. The significance of high levels of lipoprotein (a) compared with established risk factors in premature coronary artery disease: differences between men and women. Atherosclerosis. 1999;144:221–228[CrossRef][ISI][Medline]
  55. Shlipak MG, Simon JA, Vittinghoff E. Estrogen and progestin, lipoprotein (a) and the risk of recurrent coronary heart disease events after menopause. JAMA. 2000;283:1845–1852[Abstract/Free Full Text]
  56. Burt VL, Whelton P, Roccella EJ. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutritional Examination Survey, 1988–1991. Hypertension. 1995;25:305–313[Abstract/Free Full Text]
  57. Kannel WB. Risk stratification in hypertension: new insights from the Framingham Study. Am J Hypertens. 2000;13:3S–10S[ISI][Medline]
  58. Shapiro AP, Rutan GH. Hypertension in women: differences and implications. Eaker E, Packard B, Wenger EK. Coronary heart disease in women: proceedings of an NIH workshop. New York: Haymarket Doyma; 1987. p. 172–176
  59. Brochier ML, Arwidson P. Coronary heart disease risk factors in women. Eur Heart J. 1998;19:A45–A52
  60. Corrao JM, Becker RC, Ockene IS, Hamilton GA. Coronary heart disease risk factors in women. Cardiology. 1990;77:8–12
  61. Nanchahal K, Ashton WD, Wood DA. Association between blood pressure, the treatment of hypertension, and cardiovascular risk factors in women. J Hypertens. 2000;18:833–841[CrossRef][ISI][Medline]
  62. Hughson WG, Mann JI, Garrod A. Intermittant claudication: prevalence and risk factors. Br J Med. 1978;1:1379–1381
  63. Price JF, Mowbray PI, Lee AJ, Rumley A, Lowe GDO, Fowkes FGR. Relationship between smoking and cardiovascular risk factors in the development of peripheral arterial disease and coronary artery disease. Edingburgh Artery Study. Eur Heart J. 1999;20:344–353[Abstract/Free Full Text]
  64. Doll R, Grey R, Hafner B, Peto R. Mortality in relation to smoking: 20 years' observation on female British doctors. BMJ. 1980;2:967–971
  65. Croft P, Hannaford PC. Risk factors for acute myocardial infarction in women: evidence from the Royal College of General Practitioners' oral contraception study. BMJ. 1989;298:165–168[ISI][Medline]
  66. Hu FB, Stampfer MJ, Manson JE. Trends in the incidence of coronary heart disease and changes in diet and lifestyle in women. N Engl J Med. 2000;343:530–537[Abstract/Free Full Text]
  67. MMWR Morb Mortal Wkly Rep, Cigarette smoking among adults—United States, 1994, 1996, 45, 588, 90
  68. Wagenknecht LE, Craven TE, Preisser JS, Manolio TA, Winders S, Hulley SB. Ten-year trends in cigarette smoking among young adults, 1986–1996: The CARDIA Study. Ann Epidemiol. 1998;8:301–307[CrossRef][ISI][Medline]
  69. Wenger NK, Speroff L, Packard B. Cardiovascular health and disease in women. N Engl J Med. 1993;329:247–256[Free Full Text]
  70. Stampfer MJ, Hu FB, Manson JE, Rimm EB, Willett WC. Primary prevention of coronary heart disease in women through diet and lifestyle. N Engl J Med. 2000;343:16–22[Abstract/Free Full Text]
  71. Glantz SA, Parmley WW. Passive smoking and heart disease. Epidemiology, physiology, and biochemistry. Circulation. 1991;83:1–12[Abstract/Free Full Text]
  72. Law MR, Morris JK, Wald NJ. Environmental tobacco smoke exposure and ischaemic heart disease: an evaluation of the evidence. BMJ. 1997;315:973–980[Abstract/Free Full Text]
  73. Grundy SM, Benjamin IJ, Burke GL. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 1999;100:1134–1146[Free Full Text]
  74. Lee WL, Cheung AM, Cape D, Zinman B. Impact of diabetes on coronary artery disease in women and men: a meta-analysis of prospective studies. Diabetes Care. 2000;23:962–968[Abstract]
  75. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229–234[Abstract/Free Full Text]
  76. Barrett-Connor EL, Cohn BA, Wingard DL, Edelstein SL. Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men. The Rancho Bernardo Study. JAMA. 1991;265:627–631[Abstract]
  77. Hu FB, Stampfer MJ, Solomon CG. The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20 years of follow-up. Arch Intern Med. 2001;161:1717–1723[Abstract/Free Full Text]
  78. Laakso M, Ronnemaa T, Lehto S, Puukka P, Kallio V, Pyorala K. Does NIDDM increase the risk for coronary heart disease similarly in both low- and high-risk populations? Diabetologia. 1995;38:487–493[ISI][Medline]
  79. Am J Epidemiol. 1991;133:577–584[Abstract/Free Full Text]
  80. Laing SP, Swerdlow AJ, Slater SD. The British Diabetic Association Cohort Study, II: cause-specific mortality in patients with insulin-treated diabetes mellitus. Diabet Med. 1999;16:466–471[CrossRef][ISI][Medline]
  81. Obes Res. 1998;6:51S–209S[ISI][Medline]
  82. Arch Intern Med. 1998;158:1855–1867[Free Full Text]
  83. Krauss RM, Eckel RH, Howard B. AHA Dietary Guidelines: revision 2000: A statement for healthcare professionals from the Nutrition Committee of the American Heart Association. Circulation. 2000;102:2284–2299[Free Full Text]
  84. Bedinghaus J, Leshan L, Diehr S. Coronary artery disease prevention: what's different for women? Am Fam Physician. 2001;63:1393–1400[ISI][Medline]
  85. Krauss RM, Winston M, Fletcher BJ, Grundy SM. Obesity: impact on cardiovascular disease. Circulation. 1998;98:1472–1476[Free Full Text]
  86. Willett WC, Manson JE, Stampfer MJ. Weight, weight change, and coronary heart disease in women. JAMA. 1995;273:461–465[Abstract]
  87. Dorn JM, Schisterman EF, Winkelstein W Jr, Trevisan M. Body mass index and mortality in a general population sample of men and women. The Buffalo Health Study. Am J Epidemiol. 1997;146:919–931[Abstract/Free Full Text]
  88. Schulte H, von Eckardstein A, Cullen P, Assmann G. Obesity and cardiovascular risk. Herz. 2001;26:170–177[ISI][Medline]
  89. Olson MB, Kelsey SF, Bittner V. Weight cycling and high-density lipoprotein cholesterol in women: evidence of an adverse effect: a report sponsered from the NHLBI-sponsored WISE study. Women's Ischemia Syndrome Evaluation Study Group. J Am Coll Cardiol. 2000;36:1565–1571[Abstract/Free Full Text]
  90. Williams DF. Intentional weight loss: patterns in the general population and its association with morbidity and mortality. Int J Obes Relat Metab Disord. 1997;21:S14–19
  91. Lissner L, Odell PM, D'Agostino RB. Variability of body weight and health outcomes in the Framingham population. N Engl J Med. 1991;324:1839–1844[Abstract]
  92. Vague J. The degree of masculine differentiation of obesities. Am J Clin Nutr. 1956;4:20–34[Abstract]
  93. Folsum A, Prineas R, Kaye S, Munger R. Incidence of hypertension and stroke in relation to body fat distribution and other risk factors in older women. Stroke. 1990;21:701–706[Abstract/Free Full Text]
  94. Rexrode KM, Carey VJ, Hennekens CH. Abdominal adiposity and coronary heart disease in women. JAMA. 1998;280:1843–1848[Abstract/Free Full Text]
  95. Folsom AR, Kushi LH, Anderson KE. Association of general and abdominal obesity with multiple health outcomes in older women: the Iowa Women's Health Study. Arch Intern Med. 2000;160:2117–2128[Abstract/Free Full Text]
  96. Lean MEJ, Han TS, Morrison CE. Waist circumference as a measure for indicating need for weight management. BMJ. 1995;311:158–161[Abstract/Free Full Text]
  97. Berlin JA, Colditz GA. A meta-analysis of physical activity in the prevention of coronary heart disease. Am J Epidemiol. 1990;132:612–628[Abstract/Free Full Text]
  98. Lee IM, Rexrode KM, Cook NR, Manson JE, Buring JE. Physical activity and coronary heart disease in women: Is ‘no pain, no gain’ passé? JAMA. 2001;285:1447–1454[Abstract/Free Full Text]
  99. Hu FB, Stampfer MJ, Solomon C. Physical activity and risk for cardiovascular events in diabetic women. Ann Intern Med. 2001;134:96–105[Abstract/Free Full Text]
  100. Manson JAE, Hu FB, Rich-Edwards JW. A prospective study of walking as compared with vigorous exercise in the prevention of coronary heart disease in women. N Engl J Med. 1999;341:650–658[Abstract/Free Full Text]
  101. Williams PT. High-density lipoprotein cholesterol and other risk factors for coronary heart disease in female runners. N Engl J Med. 1996;334:1298–1303[Abstract/Free Full Text]
  102. Mayer-Davis EJ, D'Agostino R Jr, Karter AJ. Intensity and amount of physical activity in relation to insulin sensitivity: the Insulin Resistance Atherosclerosis Study. JAMA. 1998;279:669–674[Abstract/Free Full Text]
  103. Hambrecht R, Wolf A, Gielen S. Effect of exercise on coronary endothelial function in patients with coronary artery disease. N Engl J Med. 2000;17;342:454–460
  104. Sesso HD, Paffenbarger RS, Ha T, Lee IM. Physical activity and cardiovascular risk in middle-aged and older women. Am J Epidemiol. 1999;150:408–416[Abstract/Free Full Text]
  105. Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med. 1999;340:115–126[Free Full Text]
  106. Tataru MC, Heinrich J, Junker R. C-reactive protein and the severity of atherosclerosis in myocardial infarction patients with stable angina pectoris. Eur Heart J. 2000;21:1000–1008[Abstract/Free Full Text]
  107. Wolbink GJ, Brouwer MC, Buysmann S, ten Berge IJ, Hack CE. CRP-mediated activation of complement in vivo: assessment by measuring circulating complement-C-reactive protein complexes. J Immunol. 1996;157:473–479[Abstract]
  108. Torzewski J, Torzewski M, Bowyer DR. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vasc Biol. 1998;18:1386–1392[Abstract/Free Full Text]
  109. Eur Heart J. 1993;14:8–17[Abstract/Free Full Text]
  110. Kuller LH, Tracy P, Shaten K, Meilahn EN. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case control study. Am J Epidemiol. 1996;144:537–547[Abstract/Free Full Text]
  111. Ridker PM, Buring JE, Shih H, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation. 1998;98:731–733[Abstract/Free Full Text]
  112. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836–843[Abstract/Free Full Text]
  113. Ridker PM, Rifai N, Pfeffer MA. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation. 1998;98:839–844[Abstract/Free Full Text]
  114. Lewis SJ, Sacks FM, Mitchell JS. Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE) Trial. J Am Coll Cardiol. 1998;32:140–146[Abstract/Free Full Text]
  115. Cushman M, Legault C, Barrett-Connor E. Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Intervention (PEPI) study. Circulation. 1999;100:717–722[Abstract/Free Full Text]
  116. JAMA. 1995;273:199–208[Abstract]
  117. Hulley S, Grady D, Bush T. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998;280:605–613[Abstract/Free Full Text]
  118. Selhub J, Jacques PF, Wilson PWF, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA. 1993;270:2693–2698[Abstract]
  119. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med. 1998;338:1042–1050[Free Full Text]
  120. Harpel PC, Zhang X, Borth W. Homocysteine and hemostasis: Pathogenic mechanisms predisposing to thrombosis. J Nutr. 1996;126:1285S–1289S[Abstract/Free Full Text]
  121. Stangl V, Günther C, Jarrin A. Homocysteine inhibits TNF-{alpha} induced endothelial adhesion molecule expression and monocyte adhesion via nuclear factor-{kappa}B dependent pathway. Biochem Biophys Res Commun. 2001;280:1093–1100[CrossRef][ISI][Medline]
  122. Arnesen E, Refsum H, Bonaa KH, Ueland PM, Forde OH, Nordrehaug JE. Serum total homocysteine and coronary heart disease. Int J Epidemiol. 1995;24:704–709[Abstract/Free Full Text]
  123. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SM. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med. 1997;337:230–236[Abstract/Free Full Text]
  124. Wald NJ, Watt HC, Law MR, Weir DG, McPartlin J, Scott JM. Homocysteine and ischemic heart disease: results of a prospective study with implications regarding prevention. Arch Intern Med. 1998;158:862–867[Abstract/Free Full Text]
  125. Alfthan G, Pekkanen J, Jauhianen M. Relation of serum homocysteine and lipoprotein (a) concentrations to atherosclerotic disease in a prospective Finnish population-based study. Atherosclerosis. 1994;106:9–19[CrossRef][ISI][Medline]
  126. Evans RW, Shaten BJ, Hempel JD, Cutler JA, Kuller LH. Homocysteine and risk of cardiovascular disease in the Multiple Risk Factor Intervention Trial. Arterioscler Thromb Vasc Biol. 1997;17:1947–1953[Abstract/Free Full Text]
  127. Folsom AR, Nieto FJ, McGovern PG. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamines: the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 1998;98:204–210[Abstract/Free Full Text]
  128. Christen WG, Ajani UA, Glynn RJ, Hennekens CH. Blood levels of homocysteine and increased risk of cardiovascular disease: causal or casual. Arch Intern Med. 2000;160:422–434[Abstract/Free Full Text]
  129. Verhoef P. Hyperhomocysteinemia and risk of vascular disease in women. Semin Thromb Hemost. 2000;26:325–334[CrossRef][ISI][Medline]
  130. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocyst(e)ine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA. 1995;274:1049–1057[Abstract]
  131. Dierkes J, Jeckel A, Ambrosch A, Westphal S, Luley C, Boeing H. Factors explaining the difference of total homocyst(e)ine between men and women in the European Investigation into Cancer and Nutrition Potsdam Study. Metabolism. 2001;50:640–645[CrossRef][ISI][Medline]
  132. Ridker PM, Manson JE, Buring JE, Shih J, Matias M, Hennekens CH. Homocyst(e)ine and risk of cardiovascular disease among postmenopausal women. JAMA. 1999;281:1817–1821[Abstract/Free Full Text]
  133. Cortellaro M, Boschetti C, Cofranscesco E. The PLAT study: hemostatic function in relation to atherothrombotic ischemic events in vascular disease patients: Principal results. PLAT Study Group. Progetto Lombardo Atero-Trombosi (PLAT) Study Group. Arterioscler Thromb Vasc Biol. 1992;12:1063–1070[Abstract/Free Full Text]
  134. Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet. 1993;342:1076–1079[CrossRef][ISI][Medline]
  135. Benderly M, Graff E, Reicher-Reiss H, Behar S, Brunner D, Goldbourt U. Fibrinogen as a predictor of mortality in coronary heart disease patients. The Bezafibrate Infarction Prevention (BIP) Study Group. Arterioscler Thromb Vasc Biol. 1996;16:351–356[Abstract/Free Full Text]
  136. Thompson SG, Kienast SG, Pyke SDM, Haverkate F, van de Loo JWC. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med. 1995;332:635–641[Abstract/Free Full Text]
  137. Thompson SG, Fechtrup C, Squire E. Antithrombin III and fibrinogen as predictors of cardiac events in patients with angina pectoris. Arterioscler Thromb Vasc Biol. 1996;16:357–362[Abstract/Free Full Text]
  138. Assmann G, Cullen P, Heinrich J, Schulte H. Hemostatic variables in the prediction of coronary risk: results from the 8-year follow-up of healthy men in the Munster Heart Study (PROCAM). Prospective Cardiovascular Munster Study. Isr J Med Sci. 1996;32:364–370[ISI][Medline]
  139. Hamsten A. The hemostatic system and coronary heart disease. Thromb Res. 1993;70:1–38[CrossRef][ISI][Medline]
  140. Smith FB, Lee AJ, Fowkes FGR, Price JF, Rumley A, Lowe GDO. Hemostatic factors as predictors of ischaemic heart disease and stroke in the Edinburgh Artery Study. Arterioscler Thromb Vasc Biol. 1997;17:3321–3325[Abstract/Free Full Text]
  141. Lee AJ, Fowkes FGR, Lowe GDO, Connor JM, Rumley A. Fibrinogen, Factor VII and PAI-1 genotypes and risk of coronary and peripheral atherosclerosis: Edinburgh Artery Study. Thromb Haemost. 1999;81:553–560[ISI][Medline]
  142. Meilahn E, Ferrell R, Kiss J. Genetic determination of coagulation factor VIIc levels among healthy middle-aged women. Thromb Haemost. 1995;73:623–625[ISI][Medline]
  143. Schenck-Gustafsson K. Risk factors for cardiovascular disease in women: assessment and management. Eur Heart J. 1996;17:2–8
  144. Vasse M, Paysant J, Soria J, Collet JP, Vannier JP, Soria C. Regulation of fibrinogen biosynthesis by cytokines, consequences on the vascular risk. Haemostasis. 1996;26:331–339
  145. Montalescot G, Collet JP, Choussat R, Thomas D. Fibrinogen as a risk factor for coronary heart disease. Eur Heart J. 1998;19:H11–H17
  146. Salomaa V, Rasi V, Pekkanen J. Haemostatic factors and prevalent coronary heart disease: the FINRISK Haemostasis Study. Eur Heart J. 1994;15:1293–1299[Abstract/Free Full Text]
  147. Folsom AR, Wu KK, Rosamond WD, Sharrett AR, Chambless LE. Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 1997;96:1102–1108[Abstract/Free Full Text]
  148. Woodward M, Lowe GDO, Rumley A, Tunstall-Pedoe H. Fibrinogen as a risk factor for coronary heart disease and mortality in middle-aged men and women. Eur Heart J. 1998;19:55–62[Abstract/Free Full Text]
  149. Eriksson M, Egberg N, Wamala S, Orth-Gomer K, Mittleman MA, Schenck-Gustafsson K. Relationship between plasma fibrinogen and coronary heart disease in women. Arterioscler Thromb Vasc Biol. 1999;19:67–72[Abstract/Free Full Text]
  150. Williams MS, Bray PF. Genetics of arterial prothrombotic risk states. Exp Biol Med. 2001;226:409–419[Abstract/Free Full Text]
  151. Jansson JH, Olofsson BO, Nilsson TK. Predictive value of tissue plasminogen activator mass concentration on long term mortality in patients with coronary artery disease. A 7-year follow-up. Circulation. 1993;88:2030–2034[Abstract/Free Full Text]
  152. Ranby M, Sundell IB, Johnson O, Ledin MC, Dahlen G. Activity of plasminogen activator inhibitor-1 (PAI-1) in a population in Northern Sweden. Fibrinolysis. 1990;4:54–55
  153. Ossei-Gerning N, Wilson IJ, Grant PJ. Sex differences in coagulation and fibrinolysis in subjects with coronary artery disease. Thromb Haemost. 1998;79:736–740[ISI][Medline]
  154. Gebara OC, Mittleman MA, Sutherland P. Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study. Circulation. 1995;91:1952–1958[Abstract/Free Full Text]
  155. Mansfield MW, Heywood DM, Grant PJ. Sex differences in coagulation and fibrinolysis in white subjects with non-insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Res. 1996;16:160–164[Abstract/Free Full Text]
  156. Aznar J, Estelles A, Tormo G. Plasminogen activator inhibitor activity and other fibrinolytic variables in patients with coronary artery disease. Br Heart J. 1988;59:535–541[Abstract/Free Full Text]
  157. Thögersen AM, Jansson JH, Boman K. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women. Circulation. 1998;98:2241–2247[Abstract/Free Full Text]
  158. Potter van Loon BJ, Kluft K, Radder JK, Blankenstein MA, Meinders AE. The cardiovascular risk factor plasminogen activator inhibitor type-1 is related to insulin resistance. Metabolism. 1993;42:945–949[CrossRef][ISI][Medline]
  159. Broadhurst P, Kelleher C, Hughes L, Imeson JD, Raftery EB. Fibrinogen, factor VII clotting activity and coronary artery severity. Atherosclerosis. 1990;85:169–173[CrossRef][ISI][Medline]
  160. Suzuki T, Yamauchi K, Matsushita T. Elevation of factor VII activity and mass in coronary artery disease of varying severity. Clin Cardiol. 1991;14:731–736[ISI][Medline]
  161. Heinrich J, Balleisen L, Schulte H, Assmann G, van de Loo J. Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men. Arterioscler Thromb. 1994;14:54–59[Abstract/Free Full Text]
  162. Junker R, Heinrich J, Schulte H, van de Loo J, Assmann G. Coagulation factor VII and the risk of coronary heart disease in healthy men. Arterioscler Thromb Vasc Biol. 1997;17:1539–1544[Abstract/Free Full Text]
  163. Folsom AR, Wu KK, Rasmussen M, Chambless LE, Aleksic N, Nieto FJ. Determinants of population changes in fibrinogen and factor VII over 6 years. The Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb Vasc Biol. 2000;20:601–606[Abstract/Free Full Text]
  164. Miller GJ, Stirling Y, Esnouf MP. Factor VII-deficient substrate plasmas depleted of protein C raise the sensitivity of the factor VII bio-assay to activated factor VII: an international study. Thromb Haemost. 1994;71:38–48[ISI][Medline]
  165. Eriksson-Berg M, Silveira A, Orth-Gomer K, Hamsten A, Schenck-Gustafsson K. Coagulation factor VII in middle-aged women with and without coronary heart disease. Thromb Haemost. 2001;85:787–792[ISI][Medline]
  166. Gensini GF, Comeglio M, Colella A. Classical risk factors and emerging elements in the risk profile for coronary artery disease. Eur Heart J. 1998;19:A53–A61
  167. Gohlke-Bärwolf C. Coronary artery disease—is menopause a risk factor? Basic Res Cardiol. 2000;95:I/77–I/83
  168. Oliver MF, Boyd GS. Effect of bilateral ovariectomy on coronary artery disease and serum lipids. Lancet. 1959;2:690–694[CrossRef][ISI][Medline]
  169. Colditz GA, Stampfer MJ, Willett WC, Rosner B, Speizer FE, Hennekens CH. A prospective study of parental history of myocardial infarction and coronary heart disease in women. Am J Epidemiol. 1986;123:48–58[Abstract/Free Full Text]
  170. Grodstein F, Stampfer MJ, Manson JE. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med. 1996;335:453–461[Abstract/Free Full Text]
  171. Van der Schouw YT, van der Graf Y, Steyerberg EW, Eijkemans MJC, Banga JD. Age at natural menopause as a risk factor for cardiovascular mortality. Lancet. 1996;347:714–718[CrossRef][ISI][Medline]
  172. Dallongeville J, Marecaux N, Isorez D, Zylbergberg G, Fruchart JC, Amouyel P. Multiple coronary heart disease risk factors are associated with menopause and influenced by substitutive hormonal therapy in a cohort of French women. Atherosclerosis. 1995;118:123–133[CrossRef][ISI][Medline]
  173. Akahoshi M, Soda M, Nakashima E, Shimaoka K, Seto S, Yano K. Effects of menopause on trends of serum cholesterol, blood pressure and body mass index. Circulation. 1996;94:61–66[Abstract/Free Full Text]
  174. Peters HW, Westendorp IC, Hak AE. Menopausal status and risk factors for cardiovascular disease. J Intern Med. 1999;246:521–528[CrossRef][ISI][Medline]
  175. Trémollières FA, Pouilles JM, Cauneille C, Ribot C. Coronary heart disease risk factors and menopause: a study in 1684 French women. Atherosclerosis. 1999;142:415–423[CrossRef][ISI][Medline]
  176. Scarabin PY, Plu-Bureau G, Bara L, Bonithon-Kopp C, Guize L, Samama MM. Haemostatic variables in menopausal status: influence on hormone replacement therapy. Thromb Haemost. 1993;70:584–587[ISI][Medline]
  177. Taddei S, Virdis A, Ghiadoni L. Menopause is associated with endothelial dysfunction in women. Hypertension. 1996;28:576–582[Abstract/Free Full Text]
  178. Walsh BW, Schiff I, Rosner B, Greenberg L, Ravnikar V, Sacks FM. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med. 1991;325:1196–1204[Abstract]
  179. Gerhard M, Walsh BW, Tawakol A. Estradiol therapy combined with progesterone and endothelium-dependent vasodilation in postmenopausal women. Circulation. 1998;98:1158–1163[Abstract/Free Full Text]
  180. Koh KK, Cardillo C, Bui MN. Vascular effects of estrogen and cholesterol-lowering therapies in hypercholesterolemic postmenopausal women. Circulation. 1999;99:354–360[Abstract/Free Full Text]
  181. Collins P, Rosano GM, Sarrel PM. 17 beta-Estradiol attenuates acetylcholine-induced coronary arterial constriction in woen but not men with coronary heart disease. Circulation. 1995;92:24–30[Abstract/Free Full Text]
  182. Herrington DM, Reboussin DM, Brosnihan KB. Effects of estrogen replacement on the progression of coronary artery atherosclerosis. N Engl J Med. 2000;343:522–529[Abstract/Free Full Text]
  183. Ridker PM, Hennekens CH, Rifai N, Buring JE, Manson JE. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation. 1999;100:713–716[Abstract/Free Full Text]
  184. Pastinen T, Perola M, Niini P. Array-based multiplex analysis of candidate genes reveals two independent and additive genetic risk factors for myocardial infarction in the Finnish population. Hum Mol Gen. 1998;7:1453–1462[Abstract/Free Full Text]
  185. Jukema JW, Kastelein JJ. Tailored therapy to fit individual profiles. Genetics and coronary artery disease. Ann N Y Acad Sci. 2000;902:17–24[Abstract/Free Full Text]
  186. Breslow JL. Genetics of lipoprotein abnormalities associated with coronary heart disease susceptibility. Annu Rev Genet. 2000;34:233–254[CrossRef][ISI][Medline]
  187. Talmud PJ, Humphries SE. Genetic polymorphisms, lipoproteins and coronary artery disease risk. Curr Opin Lipidol. 2001;12:405–409[CrossRef][ISI][Medline]
  188. Friedlander Y, Arbogast P, Schwartz SM. Family history as a risk factor for early onset myocardial infarction in young women. Atherosclerosis. 2001;156:201–207[CrossRef][ISI][Medline]
  189. Rissanen AM, Nikkila EA. Coronary artery disease and its risk factors in families of young men with angina pectoris and in controls. Br Heart J. 1977;39:875–883[Free Full Text]
  190. Thordarson O, Fridriksson S. Aggregation of deaths from ischaemic heart disease among first-and second degree relatives of 108 males and 42 females with myocardial infarction. Acta Scand Med. 1979;205:493–500[ISI][Medline]
  191. Douglas PS, Ginsburg GS. The evaluation of chest pain in women. N Engl J Med. 1996;334:1311–1315[Free Full Text]
  192. Sesso HD, Lee IM, Gaziano JM, Rexrode KM, Glynn RJ, Buring JE. Maternal and paternal history of myocardial infarction and risk of cardiovascular disease in men and women. Circulation. 2001;104:393–398[Abstract/Free Full Text]
  193. Marenberg ME, Risch N, Berkman LF, Floderus B, de Faire U. Genetic susceptibility to death from coronary heart disease in a study of twins. N Engl J Med. 1994;330:1041–1046[Abstract/Free Full Text]
  194. Pastinen T, Perola M, Ignatius J. Dissecting a population genome for targeted screening of disease mutations. Hum Mol Genet. 2001;10:2961–2972[Abstract/Free Full Text]
  195. Funke H, Assmann G. Strategies for the assessment of genetic coronary artery disease risk. Curr Opin Lipidol. 1999;10:285–291[CrossRef][ISI][Medline]
  196. Doevendans PA, Jukema W, Spiering W, Defesche JC, Kastelein JJP. Molecular genetics and gene expression in atherosclerosis. Int J Cardiol. 2001;80:161–172[CrossRef][ISI][Medline]
  197. Frank MB, Reiner AP, Schwartz SM. The Kozak sequence polymorphism of platelet glycoprotein Ibalpha and risk of nonfatal myocardial infarction and nonfatal stroke in young women. Blood. 2001;97:875–879[Abstract/Free Full Text]
  198. Ridker PM, Stampfer MJ. Assessment of genetic markers for coronary thrombosis: promise and precaution. Lancet. 1999;353:687–688[CrossRef][ISI][Medline]
  199. Karasek RA, Theorell T, Schwartz JE. Job characteristics in relation to the prevalence of myocardial infarction in the US Health Examination Survey (HES) and the Health and Nutrition Examination Survey (HANES). Am J Public Health. 1988;78:910–918[Abstract/Free Full Text]
  200. Theorell T, Tsutsumi A, Hallquist J. Decision latitude, job strain, and myocardial infarction: a study of working men in Stockholm. The SHEEP Study Group. Stockholm Heart Epidemiology Program. Am J Public Health. 1998;88:382–388[Abstract/Free Full Text]
  201. Rozanski A, Blumenthal JA, Kaplan J. Impact of psychological factors on the pathogenesis of cardiovascular disease and implication for therapy. Circulation. 1999;99:2192–2217[Abstract/Free Full Text]
  202. Steptoe A, Marmot M. The role of psychobiological pathways in socio-economic inequalities in cardiovascular disease risk. Eur Heart J. 2002;23:13–25[Free Full Text]
  203. Eaker ED. Psychosocial risk factors for coronary heart disease in women. Cardiol Clin. 1998;16:103–111[CrossRef][Medline]
  204. Orth-Gomer K, Horsten M, Wamala SP. Social relations and extent and severity of coronary artery disease: The Stockholm Female Coronary Risk Study. Eur Heart J. 1998;19:1648–1656[Abstract/Free Full Text]
  205. Haynes SG, Feinleib M, Kannel WB. The relationship of psychosocial factors to coronary heart disease in the Framingham Study. III. Eight-year incidence of coronary heart disease. Am J Epidemiol. 1980;111:37–58[Abstract/Free Full Text]
  206. MacDougall JM, Dembroski TM, Dimsdale JE, Hackett TP. Components of type A, hostility, and anger-in: further relationships to angiographic findings. Health Psychol. 1985;4:137–152[CrossRef][ISI][Medline]
  207. Wamala SP, Mittleman MA, Schenck-Gustafsson K, Orth-Gomer K. Potential explanations of the educational gradient in coronary heart disease: a population based case-control study of Swedish women. Am J Public Health. 1999;89:315–321[Abstract/Free Full Text]
  208. Wamala SP, Mittleman MA, Horsten M, Schenck-Gustafsson K, Orth-Gomer K. Job stress and the occupational gradient in coronary heart disease in women: The Stockholm Female Coronary Risk Study. Soc Sci Med. 2000;51:481–489[CrossRef][ISI][Medline]
  209. Orth-Gomer K, Wamala SP, Horsten M, Schenck-Gustafsson K, Schneiderman N, Mittleman MA. Marital stress worsens prognosis in women with coronary heart disease: The Stockholm Female Coronary Risk Study. JAMA. 2000;284:3008–3014[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Eur Heart JHome page
V. Stangl, V. Witzel, G. Baumann, and K. Stangl
Current diagnostic concepts to detect coronary artery disease in women
Eur. Heart J., March 2, 2008; 29(6): 707 - 717.
[Abstract] [Full Text] [PDF]

Home page
 Postgrad. Med. J.Home page
W. Shu, W. Lei, and S. Peng
Recent development of ischaemic heart disease in sex difference
Postgrad. Med. J., April 1, 2007; 83(978): 240 - 243.
[Abstract] [Full Text] [PDF]

Home page
 ICVTSHome page
S. Karthik, N. Tahir, B. Thakur, and U. Nair
Risk factor awareness and secondary prevention of coronary artery disease: are we doing enough?
Interactive CardioVascular and Thoracic Surgery, June 1, 2006; 5(3): 268 - 271.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
L. J. Shaw, C. N. Bairey Merz, C. J. Pepine, S. E. Reis, V. Bittner, S. F. Kelsey, M. Olson, B. D. Johnson, S. Mankad, B. L. Sharaf, et al.
Insights From the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study: Part I: Gender Differences in Traditional and Novel Risk Factors, Symptom Evaluation, and Gender-Optimized Diagnostic Strategies
J. Am. Coll. Cardiol., February 7, 2006; 47(3_Suppl_S): S4 - S20.
[Abstract] [Full Text] [PDF]

Home page
 StrokeHome page
P. Dick, C. Sherif, S. Sabeti, J. Amighi, E. Minar, and M. Schillinger
Gender Differences in Outcome of Conservatively Treated Patients With Asymptomatic High Grade Carotid Stenosis
Stroke, June 1, 2005; 36(6): 1178 - 1183.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
H Kesteloot
Cardiovascular risk factors in women.
Eur. Heart J., September 1, 2003; 24(18): 1700 - 1701.
[Full Text] [PDF]

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive